Chat with us, powered by LiveChat

Driving scientific progress: Latest advancements in the Lhasa Intermediates data sharing initiative

Lhasa Limited is pleased to announce the latest data release for members of the Lhasa Intermediates Consortium.

This pre-competitive data sharing initiative facilitates the anonymous sharing of genetic toxicity data for common intermediates and compounds containing functional groups of interest, helping to advance scientific understanding and improve predictive toxicology.

Thanks to the continued contributions from our Consortium members, this initiative plays a vital role in strengthening in silico tools and supporting more confident, scientifically robust risk assessments.

New data release

 

The Lhasa Intermediates 2025.1.0 database update includes:

·          2,023 new data records, bringing the total to 41,775.

·          101 new substances, increasing the total to 2,253.

·          Genetic toxicity data are now available for all 2,253 structures.

With a 5% increase in the chemical dataset, coverage continues to expand across key chemical classes relevant to drug synthesis. The valuable new data strengthen the database, with some targeted retests helping to resolve previously equivocal Ames calls.

How the Lhasa Intermediates data sharing initiative works

 

Consortium members securely contribute data from their internal portfolios or generate new data through directed testing of commercially available compounds. These compounds are selected based on substructures prioritised by Lhasa scientists and members to improve structure-activity relationship (SAR) mutagenicity predictions.

All data are anonymised and standardised before being added to the database, ensuring confidentiality and consistency across contributions. The schema is designed to capture the relevant information needed to demonstrate the reliability of these proprietary data for regulatory use. This collaborative data sharing helps avoid duplicated testing and enables the use of shared data in regulatory submissions.

This latest update further supports our members in making informed, evidence-based decisions in risk assessment, while contributing to the collective advancement of predictive toxicology.

Get in touch to learn how your organisation can benefit from collaborative data sharing and improved risk assessment capabilities.